TLPH (Talphera) Valuation Rank


TLPH Talphera Inc TLPH
34 GF Score
Price $1.03
! 3 Warning Signs
View Full Analysis

What is Talphera Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Talphera Valuation Rank Related Terms

TLPH
34GF Score
Talphera Inc TLPH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Talphera Business Description

Other Exchanges R5XA:Germany
Address 1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
34GF Score

Get the complete analysis for TLPH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.03
Price